• About us
• Contact

Advertisement

Person › Details

Paul J. Hasting ()

Hastings, Paul J. (Nkarta 291802– CEO before OncoMed 200601– CEO before QLT Inc CEO)

 

Record changed: 2023-01-03

Advertisement

More documents for Paul J. Hasting

• [1] Nkarta Inc.. (4/25/22). "Press Release: Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs". South San Francisco, CA....
• [2] CRISPR Therapeutics AG. (5/6/21). "Press Release: CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer". Zug, Cambridge, MA & South San Francisco, CA....
• [3] Nkarta Inc.. (12/10/18). "Press Release: Nkarta Therapeutics Announces Appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer". South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.